Open-Label, Phase II Trial of Isatuximab for Patients With Refractory

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04188678` - Resiliency in Older Adults Undergoing Bone Marrow Transplant	N/A
Completed	`NCT03654404` - A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients	N/A
Recruiting	`NCT06116032` - Immune Profiling for Cancer Immunotherapy Response
Recruiting	`NCT04955938` - A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms	Phase 1
Recruiting	`NCT06119685` - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers	Phase 1/Phase 2
Not yet recruiting	`NCT05391490` - Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies	Phase 1
Recruiting	`NCT05709522` - Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
Completed	`NCT00186225` - Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors	N/A
Active, not recruiting	`NCT05147311` - Positive Psychology Intervention In HSCT	N/A
Recruiting	`NCT04372524` - Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
Completed	`NCT01957579` - A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies	Phase 1
Completed	`NCT00185640` - Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies	Phase 2
Withdrawn	`NCT04390542` - Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy	N/A
Completed	`NCT04419623` - A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer	Phase 1
Recruiting	`NCT04806295` - The Leukemia and Lymphoma Society (LLS) National Research Registry
Completed	`NCT00962494` - Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors	Phase 2
Completed	`NCT00185796` - TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD	Phase 2
Completed	`NCT04236063` - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Recruiting	`NCT05692713` - Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
Recruiting	`NCT06250595` - European Rare Blood Disorders Platform (ENROL)

NCT number	NCT05873205
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact	Michael Scordo, MD
Phone	646-608-3771
Email	scordom@mskcc.org
Status	Recruiting
Phase	Phase 2
Start date	July 21, 2023
Completion date	June 29, 2026

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms